Azacitidine and Venetoclax for MRD
A Phase 2 Study of Azacitidine and Venetoclax to Treat Acute Myeloid Leukemia Patients With Measurable Residual Disease Before an Allogeneic Stem Cell Transplant
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 30 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Tags
- Chemotherapy, Hypomethylating Agents (HMA), Minimal Residual Disease (MRD), Pre-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 5 months ago
- SparkCures ID
- 2043
- NCT Identifier
- NCT06773208
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.